KASMEJ

Kastamonu Medical Journal regularly publishes internationally qualified issues in the field of Medicine in the light of up-to-date information.

EndNote Style
Index
Original Article
The seroprevalence of rubella virus in children between 0-15 years old in a hospital in Ankara province before expanded immunization program
Aims: In this study, it was aimed to determine the seroprevalence of rubella in children aged 0-15, who was admitted to Ankara Training and Research Hospital Pediatric Outpatient Clinic for various reasons between December 2001 and July 2002. In this descriptive study, it is thought that knowing the seroprevalence before the national vaccination program will be important for the evaluation of the future data.
Methods: In this descriptive study; the seroprevalence of rubella in 1170 children aged 0-15 years was investigated. The age, gender, socio-economic level and number of siblings of the 954 cases included in the study were recorded on the prepared forms, and the history of infection was taken from their families. Rubella specific IgG levels from serum samples of the cases were measured by using the RADIM rubella IgG EIA kit with Micro-ELISA technique.
Results: The average age of the children included in the study was found to be 76 ± 49 months. Considering their gender, 56.9% (n=543) were male and 43.1% (n=411) were female. Considering their socio-economic levels; 550 children were in the low income group, 393 children were in the middle income group and 11 children were in the high income group. When the distributions are evaluated according to the number of siblings; 14% (n=134) of the cases were a single child, 45% (n=426) had one sibling, 28% (n=267) had two siblings, and 13% (n=127) of the cases had ? 3 siblings. When evaluated in terms of rubella seroprevalence, 47.2% (n=450) of the cases had negative rubella IgG and 52.8% (n=504) of them had positive rubella IgG. According to the age the seropositivity showed a significant increase with the increasing age and remained constant at around 91% in the 13-15 age range (p <0.05).
Conclusion: This study, conducted before the National Immunization Program in 2003, showed that a large part of our population is vulnerable to the risk of rubella infection. Considering that the seroprevalence increases with age in order to prevent rubella infection, which affects women of reproductive age and congenital rubella syndrome (CRS) seen in newborns in particular, it is important to vaccinate all children who have completed their 12th month and have entered the 48th month within the scope of the national vaccination program. The data of this study will guide us in evaluating the success of the program in the population, we provide healthcare services in the following years, as it reflects the situation before the Expanded Immunization Program (EIP).


1. George S, Viswanathan R, Sapkal G.N. Molecular aspects of the teratogenesis of <em>Rubellavirus. </em>Biol. Res. 2019;52: 47.
2. Aynali A, Cicioğlu Arıdoğan B, Tola E, &Ouml;nal S, Sesli &Ccedil;etin E. Doğurganlık yaş grubundaki kadınlarda <em>Rubella</em> IgM ve IgG seroprevalansı. SD&Uuml; Sağlık Bilimleri Enstit&uuml;s&uuml; Dergisi. 2016; 7(1): 10-3.
3. Leung A. KC, Hon KL, Leong KF. <em>Rubella</em> (German measles) revisited. Hong Kong Med J. 2019; 25: 134-41.
4. Kul M, Hacıhamdioğlu D, G&uuml;lg&uuml;n M, ve ark. Doğumsal kızamık&ccedil;ık sendromu. Gulhane Med J 2005; 47: 312-14.
5. Tyor W, Harrison T. Mumps and <em>Rubella. </em>Handb Clin Neurol. 2014; 123: 591-600.
6. Duszak R.S. Congenital <em>Rubella </em>syndrome&mdash;major review. Optometry. 2009; 80(1): 36-43.
7. Kirby T. <em>Rubella</em> is eliminated from the Americas. Lancet Infect Dis. 2015; 15: 768-9.
8. Yapıcı G, Yeniocak Tun&ccedil; A. &Uuml;lkemizde aşı ile korunulabilen hastalıklara y&ouml;nelik y&uuml;r&uuml;t&uuml;len eliminasyon ve eradikasyon programlarının değerlendirilmesi. Lokman Hekim Journal. 2019; 9 (2): 171-183.
9. Taneja DK.,Sharma P. Targeting <em>Rubella </em>for elimination. Indian J Public Health. 2012; 56(4): 269-72.
10. WHO. Global measles and <em>Rubella </em>strategic plan: 2012-2020. Geneva, Switzerland.( file:///C:/Users/hp/Downloads/9789241503396_eng.pdf).
11. Grant GB. Progress in <em>Rubella </em>and Congenital <em>Rubella </em>syndrome control and elimination-worldwide, 2000-2016. MMWR. 2017; 66(45): 1256-60.
12. Karakaş A, T&uuml;rker T, Arslan E, Turhan V. Van ilindeki &ouml;zel bir tıp merkezine başvuran doğurganlık &ccedil;ağındaki kadınlarda <em>Rubella </em>duyarlılığının araştırılması. Turk Hij Den Biyol Derg; 2010; 67(4): 179-84.
13. <a href="http://www.asisempozyumu.org">www.asisempozyumu.org</a>. 06.04.2021
14. <a href="https://asi.saglik.gov.tr/asi-takvimi2">https://asi.saglik.gov.tr/asi-takvimi2</a>. 06.04.2021.
15. Voller A, Bidwell DE. Enzyme immuno assays for antibodies in measles, <em>Cytomegalovirus</em> infections an after <em>Rubella </em>vaccination. Br J ExpPathol. 1976; 57: 243.
16. G&uuml;rg&ouml;ze MK, Yılmaz E, G&ouml;dekmerdan A, Ak&ccedil;a Z, Doğan Y. Seroprevalance of Mumps, <em>Varicella </em>and <em>Rubella </em>antibodies in children 1-16 years of age in eastern Turkey. Turk J Pediatr. 2006; 48:185-8.
17. Şener K, Kılı&ccedil; A, G&uuml;ney &Ccedil;, A&ccedil;ıkel C.H, G&uuml;l H.C, Başustaoğlu AC. Genişletilmiş Bağışıklama Programı &ouml;ncesi Rubella (kızamık&ccedil;ık) seroprevalansı. TAF Prev Med Bull.2007; 6(5): 371-74.
18. Dilli D, Dallar Y, &Ouml;nde U, Doğan F, Yağcı S. Ergenlerde kızamık, kızamık&ccedil;ık, kabakulak ve su&ccedil;i&ccedil;eği seroprevalansı. &Ccedil;ocuk Derg. 2008;8(3): 172-8.
19. &Ccedil;elik S, &Ccedil;elik N, G&uuml;ltekin A. ve ark. Sivas il merkezinde dokuz-on altı yaş grubu &ccedil;ocuklarda kızamık, kızamık&ccedil;ık ve kabakulak seroprevalansının araştırılması. &Ccedil;ocuk Derg. 2011; 11(3): 108-13.
20. Ayta&ccedil; N, Yapıcıoğlu AB, &Ccedil;etinalp S, Kibar F, Kara&ouml;merlioğlu &Ouml;. Kızamık&ccedil;ık aşısı ile aşılanmamış doğurgan &ccedil;ağ evli kadınlarda kızamık&ccedil;ık duyarlılığı. TSK Koruyucu Hekim Bul. 2007; 6(1): 9-16.
21. Karabulut A, Polat Y, T&uuml;rk M, Işık Balcı Y. Denizli b&ouml;lgesinde gebe kadınlarda <em>Rubella, Toxoplasmagondii</em> ve <em>Sitomegalovir&uuml;s </em>seroprevalansının değerlendirilmesi. Turk J MedSci. 2011; 41(1): 159-64.
22. &Ccedil;opur &Ccedil;i&ccedil;ek A, Duygu F. Şanlıurfa ilindeki doğurganlık &ccedil;ağındaki kadınlarda <em>Rubella</em> antikorlarının araştırılması. Dicle Med J. 2012; 39(2): 174-8.
23. Doğan Toklu G. Gebelerde <em>Toxoplazma, Rubellavirus</em> ve <em>Sitomegalovir&uuml;s</em>&rsquo;a karşı oluşan antikorların sıklığı. J Clin Anal Med. 2013; 4(1): 38-40.
24. T&uuml;re Z, Ulu Kılı&ccedil; A, Cevahir F, Demiraslan H, G&ouml;kahmetoğlu S, Alp E. Sağlık &ccedil;alışanlarında <em>Hepatit B,</em> kızamık, kızamık&ccedil;ık, kabakulak ve su&ccedil;i&ccedil;eğinde bağışıklık oranları. FLORA. 2013; 18(2): 98-102.
25. Devecioğlu E, G&ouml;k&ccedil;ay G, Boran P, Eren T, Yılmaz G, Badur S. İlk altı ayda maternal kızamık, kızamık&ccedil;ık, kabakulak ve su&ccedil;i&ccedil;eği antikorlarının durumu. Mikrobiyol Bul. 2018; 52(3): 324-7.
26. Yenilmez E, &Ccedil;etinkaya R.A. Hemşire adayı stajyerlerde <em>Hepatit </em>- <em>HIV </em>seroprevalansı ve aşı ile korunabilinen hastalıklara karşı imm&uuml;nizasyon oranları. J Ankara Univ Fac Med 2019; 72(2): 174-8.
27. Kaya Aksoy G, Sağlık İ, Velipaşaoğlu S. ve ark. &Ccedil;ocuk b&ouml;brek nakli alıcılarında viral seroprevalans. Turk Pediatr Ars. 2020; 55(4): 418-24.
28. Kara Uzun A. Sağlık meslek lisesi &ouml;ğrencilerinin <em>Hepatit B, Hepatit A,</em> kızamık, kızamık&ccedil;ık, kabakulak ve su&ccedil;i&ccedil;eği antikor seroprevalanslarının değerlendirilmesi. J Contemp Med. 2020; 10(2): <em>201-6. </em>
29. &Ccedil;ubuk F, Hasbek M, Taşkın Kafa A. H, &Ccedil;elik C. Hastanemize başvuran gebelerde <em>Toksoplazma, Rubellavir&uuml;s</em> ve <em>Sitomegalovirus</em> enfeksiyonları i&ccedil;in serolojik g&ouml;stergelerin değerlendirilmesi. Turk Mikrobiyol Cemiy Derg. 2020; 50(4): 211-7.
30. Genişletilmiş Bağışıklama Programı Genelgesi. <a href="https://www.saglik.gov.tr/TR,11080/genisletilmis-bagisiklama-programi%20genelgesi.html.%2007.04.2021">https://www.saglik.gov.tr/TR,11080/genisletilmis-bagisiklama-programi genelgesi.html. 07.04.2021</a>.
Volume 1, Issue 2, 2021
Page : 41-45
_Footer